A new report by visiongain forecasts that the world market for sexual dysfunction drugs will reach $7.7 billion in 2019, rising further to 2026. That revenue prediction and others appear in Male and Female Sexual Dysfunctions: Drug Market Report and Forecasts 2016-2026, Exploring Prospects for Companies Treating Erectile Dysfunction, Peyronie’s Disease, Female Hypoactive Sexual Desire Disorder and Other Conditions. That study appears in December 2015. Visiongain is a business information publisher and consultancy in London, UK.

That new analysis predicts the global sexual dysfunction drugs market will decline at a CAGR of -0.3% from 2014 to 2020 and then expand again. Overall revenues will increase from 2015 to 2026. Worldwide revenue, overall, will decline during the first half of the forecast period owing to loss of patent exclusivity of blockbuster drugs and prominence of generic medicines. The market will be stimulated by ageing populations, rising incidence of cardiovascular and metabolic disorders, new drug delivery technologies, emerging test techniques and the rising female sexual dysfunction drugs submarket.

Approval of the first drugs for Peyronie’s disease and female hypoactive sexual desire disorder form important breakthroughs that will bolster underserved submarkets. The female sexual dysfunction drugs submarket, which has been overshadowed by the male treatments submarket, has finally received more attention from pharmaceutical companies, healthcare practitioners and regulatory bodies.

Sandra Wenas, a senior pharmaceutical industry analyst in visiongain, said: “We believe that there will be positive changes in the way societies perceive male and female sexual dysfunctions. Increased awareness and more self reporting will expand the size of patient populations. Presently there is still divided opinion on whether female sexual dysfunction is a physiological disease that needs medication or whether it is a psychological condition. This difference in opinion stems, first, from the lack of understanding of the pathophysiology of female sexual dysfunction. Second, debate results from the lack of established assessment tools and parameters to define when symptoms indicate female sexual dysfunction.

“Budgetary constraints form a hurdle for other therapeutic markets, and even more so for the sexual disorders treatment market. Many countries’ healthcare systems still perceive sexual dysfunction as less of a priority, despite the fact that patients with untreated sexual dysfunction can fall into depression, hence resulting in socioeconomic consequences. The female sexual dysfunction drugs market, especially, will face even more difficulty in justifying cost effectiveness, given that no universally agreed systems are available to measure clinical efficacy. Cultural views can also slow the rate of understanding those disorders, thus reducing sales of treatments.”

The recent FDA approval of Addyi (flibanserin), for hypoactive sexual desire disorder (HSDD), gives a breakthrough for female sexual dysfunction treatment. The approval of Addyi will drive the market, as that condition has now received more attention, encouraging women with HSDD to address that topic with doctors. Suppliers of treatments will benefit from that therapy and others serving that large under-met medical need.

Visiongain’s investigation shows revenue forecasts to 2026 at overall world market, submarket, product and national level. It also discusses R&D, medical, technological and commercial trends and reviews that industry’s leading companies. Those organisations include Eli Lilly, Pfizer, Merck KGaA, Merck & Co., Ipsen and Bayer.

The study forecasts revenues to 2026 for these submarkets at world level:

• PDE5 inhibitors
• Prostaglandins
• Androgens
• Gonadotrophins
• Other drug classes (grouped).

That work also divides the world market into overall revenues for male and female treatments as two categories. Furthermore the report assesses emerging therapies: Vitaros, Addyi and Xiapex.

In addition, the study gives 14 product-level forecasts, including for these brands:

• Cialis
• Viagra
• Gonal-F
• Levitra
• Nebido
• Testim
• Priligy
• Tostran.

Further analyses predict overall treatment revenues to 2026 for leading countries:

• US
• Japan
• Germany, France, UK, Spain, Italy (EU5)
• Brazil, Russia, India, China (BRIC)
• Rest of world (grouped analysis).

Visiongain forecasts that BRIC countries will show the fastest revenue growth and account for 17% of the overall world market by 2026. The rise of those regions’ revenues will be driven, in particular, by sales in China and India, both showing high promise for business expansion.

Male and Female Sexual Dysfunctions: Drug Market Report and Forecasts 2016-2026 adds to visiongain’s analytical reports on industries and markets in healthcare. Those studies cover pharmaceuticals, biotechnologies, medical devices, diagnostics and outsourced services.